Antifungal expenditures manuscript revised changes accepted.pdf (627.97 kB)

Influence of drug class and healthcare setting on systemic antifungal expenditures in the United States, 2005–15

Download (627.97 kB)
journal contribution
posted on 18.06.2018, 00:00 by Margaret A. Fitzpatrick, Katie J. Suda, Charlesnika T. Evans, Robert J. Hunkler, Frances Weaver, Glen T. Schumock
Purpose Overall and specific class trends in systemic antifungal expenditures in various U.S. healthcare settings from 2005 through 2015 were evaluated. Methods Systemic antifungal expenditures from January 1, 2005, through December 31, 2015, were obtained from the QuintilesIMS National Sales Perspective database, which provides a statistically valid projection of medication purchases from multiple markets throughout the United States. Summary data for total antifungal expenditures over the entire period are reported, as are growth and the percentage change in expenditures from one year to the next. Expenditures were also assessed specifically by year, class, and healthcare setting. Expenditure trends over the study period were assessed using simple linear trend regression models. Results Overall expenditures for the 11-year period were $9.37 billion. The greatest proportion of expenditures occurred in nonfederal hospitals (47.2%) and for triazoles (57.6%). From 2005 through 2015, total expenditures decreased from $1.1 billion to $894 million (−18.8%, p = 0.09); however, expenditures in clinics and retail pharmacies increased (202%, p < 0.01, and 13.8%, p = 0.04, respectively), a trend most pronounced after 2012. Expenditures for flucytosine also increased (968.1%, p < 0.01), particularly in clinics where there was a dramatic 6,640.9% increase (p < 0.01). Conclusion From 2005 through 2015, an increase in systemic antifungal expenditures was observed in community settings, despite an overall decrease in total antifungal expenditures in the United States. Large increases in flucytosine expenditures were observed, particularly in the community.

Funding

This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service Postdoctoral Fellowship Award [grant number TPR 42-005] to M.F

History

Publisher Statement

Copyright @ American Society of Health-System Pharmacists

Citation

Fitzpatrick, M. A., Suda, K. J., Evans, C. T., Hunkler, R. J., Weaver, F. and Schumock, G. T. Influence of drug class and healthcare setting on systemic antifungal expenditures in the United States, 2005-15. American Journal of Health-System Pharmacy. 2017. 74(14): 1076-1083. 10.2146/ajhp160943

Publisher

American Society of Health-System Pharmacists

Language

en_US

issn

1079-2082

Issue date

01/07/2017

Exports

Categories

Exports